Markers of response for the antiangiogenic agent bevacizumab.
about
Potential of immunomodulatory agents as adjunct host-directed therapies for multidrug-resistant tuberculosisTumor refractoriness to anti-VEGF therapyTargeted agents in epithelial ovarian cancer: review on emerging therapies and future developmentsProfile of bevacizumab and its potential in the treatment of cervical cancerOvarian Cancer Molecular Stratification and Tumor Heterogeneity: A Necessity and a ChallengeCritical appraisal of bevacizumab in the treatment of ovarian cancerRecent applications of chemosensitivity tests for colorectal cancer treatmentTrial Watch: Tumor-targeting monoclonal antibodies in cancer therapyAngiogenic inhibitors for older patients with advanced colorectal cancer: does the age hold the stage?Theranostic applications of antibodies in oncology.Biomarkers of evasive resistance predict disease progression in cancer patients treated with antiangiogenic therapies.Feasibility of novel PPP1R15A and proposed ANXA11 single nucleotide polymorphisms as predictive markers for bevacizumab regimen in metastatic colorectal cancer.Relationship between hypoxia and response to antiangiogenic therapy in metastatic colorectal cancerSerine-arginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancerMulti-scale mathematical modelling of tumour growth and microenvironments in anti-angiogenic therapyAntiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia.Strategies for modern biomarker and drug development in oncology.Antiangiogenic therapy of brain tumors: the role of bevacizumab.Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer.VEGF targets the tumour cell.Clinical potential of bevacizumab in the treatment of metastatic and locally advanced cervical cancer: current evidence.Anti-angiogenic therapy with contrast-enhanced ultrasound in colorectal cancer patients with liver metastasis.Biomarkers of reactive resistance and early disease progression during chemotherapy plus bevacizumab treatment for colorectal carcinoma.The Prognostic and Predictive Value of Carbohydrate Antigen 19-9 in Metastatic Colorectal Cancer Patients with First Line Bevacizumab Containing ChemotherapyThe emerging role of QSOX1 in cancerPrognostic significance of AMPK activation in advanced stage colorectal cancer treated with chemotherapy plus bevacizumab.Challenges in developing a validated biomarker for angiogenesis inhibitors: the motesanib experienceTissue microRNAs as predictors of outcome in patients with metastatic colorectal cancer treated with first line Capecitabine and Oxaliplatin with or without Bevacizumab.Ramucirumab: preclinical research and clinical development.Upfront FOLFOXIRI+bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer.Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agentsVEGFR targeting leads to significantly enhanced tumor uptake of nanographene oxide in vivo.Ziv-aflibercept in metastatic colorectal cancerBiomarkers for anti-angiogenic therapy in cancer.Sema3C promotes the survival and tumorigenicity of glioma stem cells through Rac1 activation.Prognostic value of CD109+ circulating endothelial cells in recurrent glioblastomas treated with bevacizumab and irinotecan.A Phase II study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast cancer.Baseline carcinoembryonic antigen (CEA) serum levels predict bevacizumab-based treatment response in metastatic colorectal cancerComputational systems biology approaches to anti-angiogenic cancer therapeutics.Immunohistological insight into the correlation between neuropilin-1 and epithelial-mesenchymal transition markers in epithelial ovarian cancer.
P2860
Q26746099-E3B4F621-F75D-47C5-AA5D-72C9FDF3EEDBQ26747678-E658364A-4C7A-4A22-9CDE-DF248DD263EAQ26750649-A3023855-1DAF-4D24-B1D5-9901472AE0E9Q26774168-8ADF88BA-E12D-4070-8EE9-F12DADCD2E00Q26777846-A87421EE-E524-4D6F-8355-1ED7EDBDAC80Q26830403-A8FA3F93-3B35-4AA2-BED5-0DE1F284051FQ26851075-F20F3DCC-41E3-48FB-B4A4-A3DD89C78288Q26993238-64DDC198-18B9-45E3-8783-6F98EAF67244Q27002538-3D692266-AEE6-4F1A-865E-4799B3C09C7CQ27693293-2F2458FE-84A3-43C4-976B-06C30DF4F5CEQ27853358-1886C33C-629E-4500-B402-8C7DD0FAF490Q27853384-FCC1BA6C-BF71-4085-B65D-1D98E30F0819Q28068654-7A0C2289-6B15-4D1E-B7E2-12D671DFFF10Q28251240-877AA2AE-67D5-4506-8945-3CAD77BBEF8EQ28818449-DE69E37E-4267-4C7F-920A-E5FFC68F570BQ30399006-E2A8C8B8-FCAC-4B24-9644-78F330BA1B18Q30590270-D6CF865D-7768-409C-A2BE-B26BFA62C5A1Q30737224-CA5B96D6-A01F-446A-93C3-74FEC7C832BCQ33418595-C1E46911-B562-48BA-8C94-B28B65C41227Q33573324-F1793DDD-CDF7-4C7B-9368-FB0D2815D62CQ33680243-B350118B-695D-48F8-BD59-E8D9715457BFQ33714320-75359CEA-E8C0-4362-B1F1-9312E4AFD5F2Q33757046-D2895507-BAE6-4448-8A52-6ED5157F982FQ33820865-EEC25C79-830C-497E-A2FE-29600F7C86A2Q33828308-24CF2EEE-BE91-48B4-83D5-8E9E48D2336BQ33877467-A2BE73B5-C661-498E-84AF-6A879CDF6BF8Q34337865-3AFE0A8D-0E6D-43EB-9A2C-8AA68CCAE3D1Q34343614-BA690672-C699-4603-8BB6-7616E07993E8Q34446310-8D312414-08BD-4884-9377-1661742BCC9AQ34492273-074799AD-C6E3-4C90-9504-327B6F8556F7Q34646376-59A2D207-AC06-4DA0-B621-C2E23F6F698CQ34650180-E4173E76-BC27-4AAD-94BD-0611DBB23279Q34658579-F036165A-0A3E-44CF-A0F3-6442E30DC62CQ34695003-30B968BA-12A0-4F96-8544-1BEC98965D45Q34714664-397E7E60-99F1-45A7-BEF1-E174C0558B16Q34999120-A5FF0E2C-D185-4D36-9930-F561E8F96E96Q35001280-6B2DA52B-2CFD-4D05-93BA-C3CAADAA1884Q35051678-A56CBADD-2BA3-4679-9D2A-4886DBD77021Q35108084-76D80049-6029-4789-A8A1-9AC923B56CD3Q35172301-181DBC42-4BD0-4A54-8FDB-1992EF813098
P2860
Markers of response for the antiangiogenic agent bevacizumab.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Markers of response for the antiangiogenic agent bevacizumab.
@en
type
label
Markers of response for the antiangiogenic agent bevacizumab.
@en
prefLabel
Markers of response for the antiangiogenic agent bevacizumab.
@en
P50
P356
P1476
Markers of response for the antiangiogenic agent bevacizumab.
@en
P2093
Sanne de Haas
Stefan J Scherer
P304
P356
10.1200/JCO.2012.46.2762
P407
P577
2013-02-11T00:00:00Z